US 9180191 B2 - Treatment Of Suicidal Ideation Or Behavior Using Inhibitors Of Nicotinic Acetylcholine Receptors - The Lens - Free & Open Patent and Scholarly Search

Patents

US 9180191 B2

Create Add Remove

Create New Collection

Make Note

Abstract

The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.

Claims

A method of treating suicidality in a subject in need thereof, comprising administering to the subject an effective amount of mecamylamine or TC-5214.
The method of claim 1, wherein the subject has suicidal thoughts and is at risk of committing suicide.
The method of claim 1, wherein the subject has tried to commit suicide or has a history of suicide attempts.
The method of claim 1, wherein the subject is further suffering from ambulatory bipolar disorder, schizophrenia, or both.
The method of claim 1, wherein the subject is identified as suffering from suicidality using a suicidality tracking scale capable of direct mapping to the Columbia Classification Algorithm for Suicide Assessment (C-CASA).
The method of claim 1, wherein the subject is identified as suffering from suicidality using the Sheehan Suicidality Tracking Scale (S-STS) or Columbia Suicide Severity Rating Scale (C-CRS).
The method of claim 1, wherein the subject is identified as having suicidality symptoms of more than zero as measured by the Sheehan Suicidality Tracking Scale (S-STS) prior to said administering.
The method of claim 1, wherein the subject has an abnormally low brain-derived neurotrophic factor (BDNF), or cerebrospinal fluid (CSF) monoamine metabolite, concentration prior to said administering.
The method of claim 8, wherein the monoamine metabolite is 5-hydroxyinoleacetic acid (5-HIAA).
The method of claim 1, wherein the subject has a polymorphism in the tryptophan hydroxylase gene in intron 7.
The method of claim 1, wherein the subject has had a major depressive episode.
The method of claim 1, wherein the subject is suffering from bipolar depression.
The method of claim 1, wherein the subject is suffering from an anxiety disorder or anxiety symptoms.
The method of claim 1, wherein the subject is further suffering from a disorder selected from the group consisting of bipolar disorder, panic disorder, social anxiety, post-traumatic stress disorder (PTSD), substance dependence/abuse, eating disorder, obsessive compulsive disorder (OCD), schizophrenia, schizo-affective disorder, schizophrenoform disorder, Huntington's disease, early Alzheimer's disease, and Parkinson's disease.
The method of claim 1, wherein the mecamylamine or TC-5214 is administered as a monotherapy.
The method of claim 1, wherein no mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication, other than an nAChR inhibitor, is administered to the subject concurrently with the mecamylamine or TC-5214, or administered less than one week prior to administration of the mecamylamine or TC-5214.
The method of claim 1, wherein the subject is administered a mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication at least one week, prior to administration of the mecamylamine or TC-5214.
The method of claim 1, wherein both mecamylamine and TC-5214 are administered to the subject.
The method of claim 1, wherein the mecamylamine is administered to the subject.
The method of claim 1, wherein the subject has not suffered a major depressive episode.
The method of claim 1, wherein the subject is not suffering from major depressive disorder.
The method of claim 1, wherein the subject is not suffering from bipolar disorder.
The method of claim 1, wherein the suicidality is thereby eliminated.
The method of claim 1, wherein the suicidality is non-drug-induced.
The method of claim 1, wherein the TC-5214 is administered to the subject.

Owners (US)

University Of South Florida (Apr 23 2012)
Explore more patents:
- View all patents where Owners (US) UNIVERSITY OF SOUTH FLORIDA

Applicants

Sheehan David Vincent
Explore more patents:
- View all patents where Applicants SHEEHAN DAVID VINCENT
Shytle Roland Douglas
Explore more patents:
- View all patents where Applicants SHYTLE ROLAND DOUGLAS
Univ South Florida
Explore more patents:
- View all patents where Applicants UNIV SOUTH FLORIDA

Inventors

Sheehan David Vincent
Explore more patents:
- View all patents where Inventors SHEEHAN DAVID VINCENT
- View all scholarly literature where Author = SHEEHAN DAVID VINCENT
Shytle Roland Douglas
Explore more patents:
- View all patents where Inventors SHYTLE ROLAND DOUGLAS
- View all scholarly literature where Author = SHYTLE ROLAND DOUGLAS

CPC Classifications

A61K2300/00
Explore more patents:
- View all patents where CPC Classifications A61K2300/00
- View in Classification Explorer
A61K31/407
Explore more patents:
- View all patents where CPC Classifications A61K31/407
- View in Classification Explorer
A61K31/55
Explore more patents:
- View all patents where CPC Classifications A61K31/55
- View in Classification Explorer
A61K31/5513
Explore more patents:
- View all patents where CPC Classifications A61K31/5513
- View in Classification Explorer
A61K33/14
Explore more patents:
- View all patents where CPC Classifications A61K33/14
- View in Classification Explorer
A61K45/06
Explore more patents:
- View all patents where CPC Classifications A61K45/06
- View in Classification Explorer

IPC Classifications

A61K31/407
Explore more patents:
- View all patents where IPC Classifications A61K31/407
- View in Classification Explorer
A61K31/55
Explore more patents:
- View all patents where IPC Classifications A61K31/55
- View in Classification Explorer
A61K31/5513
Explore more patents:
- View all patents where IPC Classifications A61K31/5513
- View in Classification Explorer
A61K33/14
Explore more patents:
- View all patents where IPC Classifications A61K33/14
- View in Classification Explorer
A61K45/06
Explore more patents:
- View all patents where IPC Classifications A61K45/06
- View in Classification Explorer
A61K8/41
Explore more patents:
- View all patents where IPC Classifications A61K8/41
- View in Classification Explorer
C07K14/705
Explore more patents:
- View all patents where IPC Classifications C07K14/705
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Nov 10, 2015
US 9180191 B2
Application: Oct 15, 2010
US 201013502239 A
Priority: Oct 15, 2010
US 201013502239 A
Priority: Oct 15, 2010
US 2010/0052949 W
Priority: Oct 16, 2009
US 25234309 P